So we, right now, are seeing data that demonstrate that our durability is about 2x of what is being noted in the clinical use of the current vaccines. There is increasingly more and more publications and statements in addressing the needs of the elderly, depending on how you define the elderly, but also those with the compromised immune systems. It’s well accepted that, that latter group of people have depleted immune systems because of various medical conditions that they are at the highest risk of severe disease, hospitalization and the risk of death. And this is, again, where we see with our construct of coming in and having a strong focus on not only on the antibody side, but also on the cellular side, given what we’re seeing right now gives us a broader, almost very agnostic immune response but also greater durability.
We think that as our product is progressing through its clinical trials, there is increasingly more and more evidence of why Project NextGen is such a critical program that the White House announced last year because it’s the recognition that what is out there is inadequate in many different ways.
Vernon Bernardino: Now as a follow-up, I didn’t attend or view the proceedings. I didn’t see any mention as far as immunocompromised individuals. Did you get any insight from the ACIP meeting about immunocompromised individuals and booster shots?
David Dodd: Not in the recent meeting, but it’s been so well underscored by the CDC, by the WHO and others that the highest-risk groups are those with compromised immune systems.
Vernon Bernardino: Okay. Yes. I’m definitely excited for that kind of clinical trial as well. Thanks for taking my question and my follow-up. Looking forward to the progress in this year.
David Dodd: Thank you so much.
Operator: [Operator Instructions] There are no further questions at this time. This concludes our question-and-answer session. I would like to turn the conference back over to David Dodd for any closing remarks.
David Dodd: Thank you, and thank you, everyone. We really appreciate your participation in this corporate update call and in joining us in sharing the achievements, progress and our outlook. And indeed, your interest is greatly appreciated. I want to especially acknowledge and thank our Board of Directors and advisers and our GeoVax staff and many other parties that continue to support and advise us towards achieving success. In achieving our success, we’re committed to providing meaningful career development opportunities for highly competitive, quality-oriented individuals seeking to disrupt the current paradigm with cancer therapies, infectious disease vaccine and redefining how success is defined in addressing various patient populations. For all of us, it’s been a great pleasure serving our shareholders, our stakeholders and being part of this team. I wish everyone a safe evening and a wonderful rest of the week. Thank you.
Operator: It’s now concluded. Thank you for attending today’s presentation. You may now disconnect.
